At 48 weeks, 93% of participants taking 12 mg achieved normal liver fat levels (below 5%), with an average 86% reduction in liver fat from baseline
OM reports grant for advisory board, speakers bureau, through Hadassah University Hospital, medical writing, support for travel, article processing charges from Novo Nordisk, a grant through Hadassah University Hospital from AstraZeneca, speakers bureau from Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, Novartis, AstraZeneca, and BOL Pharma, support for travel/meetings from AstraZeneca, and advisory board from Eli Lilly, Sanofi, Merck Sharp & Dohme, Boehringer Ingelheim, and BOL Pharma
[1][3] Research-grade Retatrutide is available only to qualified licensed professionals
As a Paloma patient, you can feel confident and in control of both your thyroid and your heart health